Cytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) shares rose 5.4% on Thursday. The stock traded as high as $6.27 and last traded at $6.2420. Approximately 504,490 shares changed hands during mid-day trading, a decline of 54% from the average session volume of 1,092,261 shares. The stock had previously closed at $5.92.
Wall Street Analyst Weigh In
A number of brokerages recently issued reports on CTKB. Weiss Ratings reiterated a "sell (d-)" rating on shares of Cytek Biosciences in a research report on Monday, September 21st. Stephens boosted their price target on shares of Cytek Biosciences from $6.00 to $7.00 and gave the company an "overweight" rating in a research report on Tuesday, November 10th. Wall Street Zen raised shares of Cytek Biosciences from a "hold" rating to a "buy" rating in a research note on Saturday, November 7th. Finally, Morgan Stanley set a $5.00 price objective on shares of Cytek Biosciences in a report on Friday, August 7th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $5.67.
Check Out Our Latest Stock Report on CTKB
Cytek Biosciences Price Performance
The company has a market capitalization of $814.13 million, a P/E ratio of -9.88 and a beta of 1.15. The stock's 50 day simple moving average is $5.56 and its two-hundred day simple moving average is $4.69.
Cytek Biosciences (NASDAQ:CTKB - Get Free Report) last released its earnings results on Wednesday, November 4th. The company reported ($0.05) earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.02. The company had revenue of $53.23 million during the quarter, compared to the consensus estimate of $53.05 million. Cytek Biosciences had a negative return on equity of 13.13% and a negative net margin of 39.10%. As a group, equities research analysts expect that Cytek Biosciences, Inc. will post -0.28 earnings per share for the current year.
Hedge Funds Weigh In On Cytek Biosciences
Several large investors have recently bought and sold shares of CTKB. Algert Global LLC boosted its position in shares of Cytek Biosciences by 1,122.6% in the 3rd quarter. Algert Global LLC now owns 182,100 shares of the company's stock worth $1,085,000 after purchasing an additional 167,205 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Cytek Biosciences by 7.2% during the third quarter. Goldman Sachs Group Inc. now owns 2,323,524 shares of the company's stock worth $13,848,000 after purchasing an additional 156,009 shares during the period. Russell Investments Group Ltd. increased its holdings in Cytek Biosciences by 60.7% in the third quarter. Russell Investments Group Ltd. now owns 2,428,747 shares of the company's stock valued at $14,475,000 after purchasing an additional 917,432 shares during the last quarter. CenterBook Partners LP increased its holdings in Cytek Biosciences by 16.0% in the third quarter. CenterBook Partners LP now owns 173,020 shares of the company's stock valued at $1,031,000 after purchasing an additional 23,840 shares during the last quarter. Finally, Squarepoint Ops LLC increased its holdings in Cytek Biosciences by 227.2% in the second quarter. Squarepoint Ops LLC now owns 82,776 shares of the company's stock valued at $367,000 after purchasing an additional 57,480 shares during the last quarter. 69.46% of the stock is currently owned by institutional investors and hedge funds.
About Cytek Biosciences
(
Get Free Report)
Cytek Biosciences develops, manufactures and sells cell analysis instruments and related products used by researchers and clinical laboratories. Its systems use flow cytometry to analyze cells and other particles, supporting work in areas such as immunology, oncology and infectious disease research. The company's product portfolio includes the Aurora and Northern Lights spectral flow cytometry systems and Amnis imaging flow cytometers. Cytek also offers reagents, software, technical support and other services that help customers prepare samples, collect and interpret data, and maintain their instruments.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cytek Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytek Biosciences wasn't on the list.
While Cytek Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.